Physician profile
Kara Eberle
NPI 1811471881
$1,693.56
in general payments reported to CMS, 2019-2025
14 companies · $338 in 2025
The $338 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $278 · 2022: $540 · 2023: $284 · 2024: $253 · 2025: $338.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $876.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $875.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $443.11 | 2021-2025 | Jardiance |
| Medtronic, INC. | $370.57 | 2021-2025 | Corevalve Evolut R |
| Novartis Pharmaceuticals Corporation | $161.23 | 2022-2025 | |
| Edwards Lifesciences Corporation | $135.47 | 2023-2024 | Sapien 3 Ultra Resilia, Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| E.R. Squibb & Sons, L.L.C. | $124.94 | 2022-2025 | Camzyos |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $120.46 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $107.71 | 2022 | |
| Abbott Laboratories | $54.26 | 2025 | Mini Trek, Diamondback Coronary |
| Alnylam Pharmaceuticals INC. | $41.02 | 2025 | Amvuttra |
| Bayer Healthcare Pharmaceuticals INC. | $37.50 | 2025 | |
| Pfizer INC. | $36.67 | 2025 | |
| Lexicon Pharmaceuticals, INC. | $31.84 | 2023-2024 | Inpefa |
| Chiesi USA, INC. | $16.09 | 2022 | |
| Lilly USA, LLC | $12.69 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kara Eberle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.